Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized phase 2 study of finafloxacin-based regimens for Helicobacter pylori eradication
2007-007749-11Phase 2Completed
- Sponsor
- MerLion Pharmaceuticals
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of finafloxacin in Helicobacter pylori infection (2 arms), sponsored by MerLion Pharmaceuticals. Primary endpoint: H. pylori eradication rate. Started Aug 2009; status: completed.
02
Drugs
finafloxacin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on 2007-007749-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007749-11.